SEC Form SC 13G/A filed by Calliditas Therapeutics AB (Amendment)

2/14/23 11:50:50 AM ET

$CALT

Biotechnology: Pharmaceutical Preparations

Health Care

Get the next $CALT alert in real time by email

SC 13G/A 1 sc13ga207422calt_02142023.htm AMENDMENT NO. 2 TO THE SCHEDULE 13G

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

SCHEDULE 13G

(Rule 13d-102)

INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT

TO RULES 13d-1(b), (c), AND (d) AND AMENDMENTS THERETO FILED

PURSUANT TO RULE 13d-2(b)

(Amendment No. 2)¹

Calliditas Therapeutics AB

(Name of Issuer)

Common Shares, quota value SEK 0.04 per share

(Title of Class of Securities)

13124Q106

(CUSIP Number)

December 31, 2022

(Date of Event Which Requires Filing of this Statement)

Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

☐

Rule 13d-1(b)

☒

Rule 13d-1(c)

☐

Rule 13d-1(d)

1 The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter disclosures provided in a prior cover page.

The information required on the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

CUSIP No. 13124Q106


	1	NAME OF REPORTING PERSON

			Biotechnology Value Fund, L.P.
	2	CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP				(a) ☒
						(b) ☐

	3	SEC USE ONLY


	4	CITIZENSHIP OR PLACE OF ORGANIZATION

			Delaware
NUMBER OF			5	SOLE VOTING POWER
SHARES
BENEFICIALLY					0
OWNED BY			6	SHARED VOTING POWER
EACH
REPORTING					3,329,608 (1)
PERSON WITH			7	SOLE DISPOSITIVE POWER

					0
			8	SHARED DISPOSITIVE POWER

					3,329,608 (1)
	9	AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

			3,329,608 (1)
	10	CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES				☐


	11	PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)

			5.6% (1)
	12	TYPE OF REPORTING PERSON

			PN

(1) Includes 807,844 Common Shares (as defined below) represented by 403,922 American Depositary Shares (“ADS”) (each ADS represents 2 Common Shares).

CUSIP No. 13124Q106


	1	NAME OF REPORTING PERSON

			BVF I GP LLC
	2	CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP				(a) ☒
						(b) ☐

	3	SEC USE ONLY


	4	CITIZENSHIP OR PLACE OF ORGANIZATION

			Delaware
NUMBER OF			5	SOLE VOTING POWER
SHARES
BENEFICIALLY					0
OWNED BY			6	SHARED VOTING POWER
EACH
REPORTING					3,329,608 (1)
PERSON WITH			7	SOLE DISPOSITIVE POWER

					0
			8	SHARED DISPOSITIVE POWER

					3,329,608 (1)
	9	AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

			3,329,608 (1)
	10	CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES				☐


	11	PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)

			5.6% (1)
	12	TYPE OF REPORTING PERSON

			OO

(1) Includes 807,844 Common Shares represented by 403,922 ADSs (each ADS represents 2 Common Shares).

CUSIP No. 13124Q106


	1	NAME OF REPORTING PERSON

			Biotechnology Value Fund II, L.P.
	2	CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP				(a) ☒
						(b) ☐

	3	SEC USE ONLY


	4	CITIZENSHIP OR PLACE OF ORGANIZATION

			Delaware
NUMBER OF			5	SOLE VOTING POWER
SHARES
BENEFICIALLY					0
OWNED BY			6	SHARED VOTING POWER
EACH
REPORTING					2,444,825 (1)
PERSON WITH			7	SOLE DISPOSITIVE POWER

					0
			8	SHARED DISPOSITIVE POWER

					2,444,825 (1)
	9	AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

			2,444,825 (1)
	10	CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES				☐


	11	PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)

			4.1% (1)
	12	TYPE OF REPORTING PERSON

			PN

(1) Includes 563,272 Common Shares represented by 281,636 ADSs (each ADS represents 2 Common Shares).

CUSIP No. 13124Q106


	1	NAME OF REPORTING PERSON

			BVF II GP LLC
	2	CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP				(a) ☒
						(b) ☐

	3	SEC USE ONLY


	4	CITIZENSHIP OR PLACE OF ORGANIZATION

			Delaware
NUMBER OF			5	SOLE VOTING POWER
SHARES
BENEFICIALLY					0
OWNED BY			6	SHARED VOTING POWER
EACH
REPORTING					2,444,825 (1)
PERSON WITH			7	SOLE DISPOSITIVE POWER

					0
			8	SHARED DISPOSITIVE POWER

					2,444,825 (1)
	9	AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

			2,444,825 (1)
	10	CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES				☐


	11	PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)

			4.1% (1)
	12	TYPE OF REPORTING PERSON

			OO

(1) Includes 563,272 Common Shares represented by 281,636 ADSs (each ADS represents 2 Common Shares).

CUSIP No. 13124Q106

NAME OF REPORTING PERSON

Biotechnology Value Trading Fund OS LP

CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP

(a) ☒

(b) ☐

SEC USE ONLY

CITIZENSHIP OR PLACE OF ORGANIZATION

Cayman Islands

NUMBER OF

SOLE VOTING POWER

BENEFICIALLY

OWNED BY

SHARED VOTING POWER

EACH

REPORTING

366,761 (1)

PERSON WITH

SOLE DISPOSITIVE POWER

SHARED DISPOSITIVE POWER

366,761 (1)

AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

366,761 (1)

CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES

☐

PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)

Less than 1% (1)

TYPE OF REPORTING PERSON

(1) Includes 95,194 Common Shares represented by 47,597 ADSs (each ADS represents 2 Common Shares).

CUSIP No. 13124Q106

NAME OF REPORTING PERSON

BVF Partners OS Ltd.

CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP

(a) ☒

(b) ☐

SEC USE ONLY

CITIZENSHIP OR PLACE OF ORGANIZATION

Cayman Islands

NUMBER OF

SOLE VOTING POWER

BENEFICIALLY

OWNED BY

SHARED VOTING POWER

EACH

REPORTING

366,761 (1)

PERSON WITH

SOLE DISPOSITIVE POWER

SHARED DISPOSITIVE POWER

366,761 (1)

AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

366,761 (1)

CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES

☐

PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)

Less than 1% (1)

TYPE OF REPORTING PERSON

(1) Includes 95,194 Common Shares represented by 47,597 ADSs (each ADS represents 2 Common Shares).

CUSIP No. 13124Q106


	1	NAME OF REPORTING PERSON

			BVF GP Holdings LLC
	2	CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP				(a) ☒
						(b) ☐

	3	SEC USE ONLY


	4	CITIZENSHIP OR PLACE OF ORGANIZATION

			Delaware
NUMBER OF			5	SOLE VOTING POWER
SHARES
BENEFICIALLY					0
OWNED BY			6	SHARED VOTING POWER
EACH
REPORTING					5,774,433 (1)
PERSON WITH			7	SOLE DISPOSITIVE POWER

					0
			8	SHARED DISPOSITIVE POWER

					5,774,433 (1)
	9	AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

			5,774,433 (1)
	10	CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES				☐


	11	PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)

			9.7% (1)
	12	TYPE OF REPORTING PERSON

			OO

(1) Includes 1,371,116 Common Shares represented by 685,558 ADSs (each ADS represents 2 Common Shares).

CUSIP No. 13124Q106


	1	NAME OF REPORTING PERSON

			BVF Partners L.P.
	2	CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP				(a) ☒
						(b) ☐

	3	SEC USE ONLY


	4	CITIZENSHIP OR PLACE OF ORGANIZATION

			Delaware
NUMBER OF			5	SOLE VOTING POWER
SHARES
BENEFICIALLY					0
OWNED BY			6	SHARED VOTING POWER
EACH
REPORTING					6,260,311 (1)
PERSON WITH			7	SOLE DISPOSITIVE POWER

					0
			8	SHARED DISPOSITIVE POWER

					6,260,311 (1)
	9	AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

			6,260,311 (1)
	10	CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES				☐


	11	PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)

			10.5% (1)
	12	TYPE OF REPORTING PERSON

			PN, IA

(1) Includes 1,500,000 Common Shares represented by 750,000 ADSs (each ADS represents 2 Common Shares).

CUSIP No. 13124Q106


	1	NAME OF REPORTING PERSON

			BVF Inc.
	2	CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP				(a) ☒
						(b) ☐

	3	SEC USE ONLY


	4	CITIZENSHIP OR PLACE OF ORGANIZATION

			Delaware
NUMBER OF			5	SOLE VOTING POWER
SHARES
BENEFICIALLY					0
OWNED BY			6	SHARED VOTING POWER
EACH
REPORTING					6,260,311 (1)
PERSON WITH			7	SOLE DISPOSITIVE POWER

					0
			8	SHARED DISPOSITIVE POWER

					6,260,311 (1)
	9	AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

			6,260,311 (1)
	10	CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES				☐


	11	PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)

			10.5% (1)
	12	TYPE OF REPORTING PERSON

			CO

(1) Includes 1,500,000 Common Shares represented by 750,000 ADSs (each ADS represents 2 Common Shares).

CUSIP No. 13124Q106


	1	NAME OF REPORTING PERSON

			Mark N. Lampert
	2	CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP				(a) ☒
						(b) ☐

	3	SEC USE ONLY


	4	CITIZENSHIP OR PLACE OF ORGANIZATION

			United States
NUMBER OF			5	SOLE VOTING POWER
SHARES
BENEFICIALLY					0
OWNED BY			6	SHARED VOTING POWER
EACH
REPORTING					6,260,311 (1)
PERSON WITH			7	SOLE DISPOSITIVE POWER

					0
			8	SHARED DISPOSITIVE POWER

					6,260,311 (1)
	9	AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

			6,260,311 (1)
	10	CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES				☐


	11	PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)

			10.5% (1)
	12	TYPE OF REPORTING PERSON

			IN

(1) Includes 1,500,000 Common Shares represented by 750,000 ADSs (each ADS represents 2 Common Shares).

CUSIP No. 13124Q106

Item 1(a).

Name of Issuer:

Calliditas Therapeutics AB, a Swedish public limited liability company (the “Issuer”).

Item 1(b).

Address of Issuer’s Principal Executive Offices:

Kungsbron 1, D5

SE-111 22

Stockholm, Sweden

Item 2(a).

Name of Person Filing

Item 2(b).

Address of Principal Business Office or, if None, Residence

Item 2(c).

Citizenship

Biotechnology Value Fund, L.P. (“BVF”)

44 Montgomery St., 40th Floor

San Francisco, California 94104

Citizenship: Delaware

BVF I GP LLC (“BVF GP”)

44 Montgomery St., 40th Floor

San Francisco, California 94104

Citizenship: Delaware

Biotechnology Value Fund II, L.P. (“BVF2”)

44 Montgomery St., 40th Floor

San Francisco, California 94104

Citizenship: Delaware

BVF II GP LLC (“BVF2 GP”)

44 Montgomery St., 40th Floor

San Francisco, California 94104

Citizenship: Delaware

Biotechnology Value Trading Fund OS LP (“Trading Fund OS”)

PO Box 309 Ugland House

Grand Cayman, KY1-1104

Cayman Islands

Citizenship: Cayman Islands

BVF Partners OS Ltd. (“Partners OS”)

PO Box 309 Ugland House

Grand Cayman, KY1-1104

Cayman Islands

Citizenship: Cayman Islands

BVF GP Holdings LLC (“BVF GPH”)

44 Montgomery St., 40th Floor

San Francisco, California 94104

Citizenship: Delaware

BVF Partners L.P. (“Partners”)

44 Montgomery St., 40th Floor

San Francisco, California 94104

Citizenship: Delaware

CUSIP No. 13124Q106

BVF Inc.

44 Montgomery St., 40th Floor

San Francisco, California 94104

Citizenship: Delaware

Mark N. Lampert (“Mr. Lampert”)

44 Montgomery St., 40th Floor

San Francisco, California 94104

Citizenship: United States

Each of the foregoing is referred to as a “Reporting Person” and collectively as the “Reporting Persons.”

Item 2(d).

Title of Class of Securities:

Common Shares, quota value SEK 0.04 per share (the “Common Shares”).

Item 2(e).

CUSIP Number:

13124Q106

Item 3.

If This Statement is Filed Pursuant to Rule 13d-1(b), or 13d-2(b) or (c), Check Whether the Person Filing is a:

	/x/	Not applicable.

(a)	/ /	Broker or dealer registered under Section 15 of the Exchange Act.

(b)	/ /	Bank as defined in Section 3(a)(6) of the Exchange Act.

(c)	/ /	Insurance company as defined in Section 3(a)(19) of the Exchange Act.

(d)	/ /	Investment company registered under Section 8 of the Investment Company Act.

(e)	/ /	An investment adviser in accordance with Rule 13d-1(b)(1)(ii)(E).

(f)	/ /	An employee benefit plan or endowment fund in accordance with Rule 13d-1(b)(1)(ii)(F).

(g)	/ /	A parent holding company or control person in accordance with Rule 13d-1(b)(1)(ii)(G).

(h)	/ /	A savings association as defined in Section 3(b) of the Federal Deposit Insurance Act.

(i)	/ /	A church plan that is excluded from the definition of an investment company under Section 3(c)(14) of the Investment Company Act.

(j)	/ /	A non-U.S. institution, in accordance with Rule 13d-1(b)(1)(ii)(J).

(k)	/ /	Group, in accordance with Rule 13d-1(b)(1)(ii)(K). If filing as a non-U.S. institution in accordance with Rule 13d-1(b)(1)(ii)(J), please specify the type of institution: ____

CUSIP No. 13124Q106

Item 4.

Ownership

(a)

Amount beneficially owned:

As of the close of business on December 31, 2022, (i) BVF beneficially owned 3,329,608 Common Shares, including 807,844 Common Shares represented by 403,922 ADSs (ii) BVF2 beneficially owned 2,444,825 Common Shares, including 563,272 Common Shares represented by 281,636 ADSs and (iii) Trading Fund OS beneficially owned 366,761 Common Shares, including 95,194 Common Shares represented by 47,597 ADSs.

BVF GP, as the general partner of BVF, may be deemed to beneficially own the 3,329,608 Common Shares beneficially owned by BVF.

BVF2 GP, as the general partner of BVF2, may be deemed to beneficially own the 2,444,825 Common Shares beneficially owned by BVF2.

Partners OS, as the general partner of Trading Fund OS, may be deemed to beneficially own the 366,761 Common Shares beneficially owned by Trading Fund OS.

BVF GPH, as the sole member of each of BVF GP and BVF2 GP, may be deemed to beneficially own the 5,774,433 Common Shares beneficially owned in the aggregate by BVF and BVF2.

Partners, as the investment manager of BVF, BVF2 and Trading Fund OS, and the sole member of Partners OS, may be deemed to beneficially own the 6,260,311 Common Shares beneficially owned in the aggregate by BVF, BVF2 and Trading Fund OS and held in a certain Partners managed account (the “Partners Managed Account”), including 119,117 Common Shares held in the Partners Managed Account, which includes 33,690 Common Shares represented by 16,845 ADSs.

BVF Inc., as the general partner of Partners, may be deemed to beneficially own the 6,260,311 Common Shares beneficially owned by Partners.

Mr. Lampert, as a director and officer of BVF Inc., may be deemed to beneficially own the 6,260,311 Common Shares beneficially owned by BVF Inc.

The foregoing should not be construed in and of itself as an admission by any Reporting Person as to beneficial ownership of any Common Shares owned by another Reporting Person. BVF GP disclaims beneficial ownership of the Common Shares beneficially owned by BVF. BVF2 GP disclaims beneficial ownership of the Common Shares beneficially owned by BVF2. Partners OS disclaims beneficial ownership of the Common Shares beneficially owned by Trading Fund OS. BVF GPH disclaims beneficial ownership of the Common Shares beneficially owned by BVF and BVF2. Each of Partners, BVF Inc. and Mr. Lampert disclaims beneficial ownership of the Common Shares beneficially owned by BVF, BVF2 and Trading Fund OS and held in the Partners Managed Account, and the filing of this statement shall not be construed as an admission that any such person or entity is the beneficial owner of any such securities.

CUSIP No. 13124Q106

(b)

Percent of class:

The following percentages are based on 59,572,587 Common Shares outstanding (including in the form of ADSs), which is the total number of Common Shares outstanding as disclosed in the Issuer’s Report of Foreign Issuer on Form 6-K filed with the Securities and Exchange Commission on December 30, 2022.

As of the close of business on December 31, 2022, (i) BVF beneficially owned approximately 5.6% of the outstanding Common Shares, (ii) BVF2 beneficially owned approximately 4.1% of the outstanding Common Shares, (iii) Trading Fund OS beneficially owned less than 1% of the outstanding Common Shares, (iv) BVF GP may be deemed to beneficially own approximately 5.6% of the outstanding Common Shares, (v) BVF2 GP may be deemed to beneficially own approximately 4.1% of the outstanding Common Shares, (vi) Partners OS may be deemed to beneficially own less than 1% of the outstanding Common Shares, (vii) BVF GPH may be deemed to beneficially own approximately 9.7% of the outstanding Common Shares and (viii) each of Partners, BVF Inc. and Mr. Lampert may be deemed to beneficially own approximately 10.5% of the outstanding Common Shares (less than 1% of the outstanding Common Shares are held in the Partners Managed Account).

(c)

Number of shares as to which such person has:

(i)

Sole power to vote or to direct the vote

See Cover Pages Items 5-9.

(ii)

Shared power to vote or to direct the vote

See Cover Pages Items 5-9.

(iii)

Sole power to dispose or to direct the disposition of

See Cover Pages Items 5-9.

(iv)

Shared power to dispose or to direct the disposition of

See Cover Pages Items 5-9.

Item 5.

Ownership of Five Percent or Less of a Class.

Not Applicable.

Item 6.

Ownership of More than Five Percent on Behalf of Another Person.

BVF GP, BVF GPH, Partners, BVF Inc. and Mr. Lampert share voting and dispositive power over the Common Shares beneficially owned by BVF. BVF GPH, Partners, BVF Inc. and Mr. Lampert share voting and dispositive power over the Common Shares beneficially owned by BVF2. Partners, BVF Inc. and Mr. Lampert share voting and dispositive power over the Common Shares beneficially owned by Trading Fund OS and held in the Partners Managed Account.

Item 7.

Identification and Classification of the Subsidiary That Acquired the Security Being Reported on by the Parent Holding Company or Control Person.

Not Applicable.

CUSIP No. 13124Q106

Item 8.

Identification and Classification of Members of the Group.

See Exhibit 99.1 to the Schedule 13G filed with the Securities and Exchange Commission on June 8, 2020.

Item 9.

Notice of Dissolution of Group.

Not Applicable.

Item 10.

Certifications.

By signing below each of the undersigned certifies that, to the best of its knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect.

CUSIP No. 13124Q106

SIGNATURE

After reasonable inquiry and to the best of his knowledge and belief, each of the undersigned certifies that the information set forth in this statement is true, complete and correct.

Dated: February 14, 2023

BIOTECHNOLOGY VALUE FUND, L.P.		BIOTECHNOLOGY VALUE TRADING FUND OS LP

By:	BVF I GP LLC, its general partner	By:	BVF Partners L.P., its investment manager
		By:	BVF Inc., its general partner
By:	/s/ Mark N. Lampert
	Mark N. Lampert	By:	/s/ Mark N. Lampert
	Chief Executive Officer		Mark N. Lampert
			President

BVF I GP LLC
		BVF GP HOLDINGS LLC
By:	/s/ Mark N. Lampert
	Mark N. Lampert	By:	/s/ Mark N. Lampert
	Chief Executive Officer		Mark N. Lampert
			Chief Executive Officer

BIOTECHNOLOGY VALUE FUND II, L.P.
		BVF PARTNERS L.P.
By:	BVF II GP LLC, its general partner
		By:	BVF Inc., its general partner
By:	/s/ Mark N. Lampert
	Mark N. Lampert	By:	/s/ Mark N. Lampert
	Chief Executive Officer		Mark N. Lampert
			President

BVF II GP LLC
		BVF INC.
By:	/s/ Mark N. Lampert
	Mark N. Lampert	By:	/s/ Mark N. Lampert
	Chief Executive Officer		Mark N. Lampert
			President

BVF PARTNERS OS LTD.
		/s/ Mark N. Lampert
By:	BVF Partners L.P., its sole member	MARK N. LAMPERT
By:	BVF Inc., its general partner

By:	/s/ Mark N. Lampert
	Mark N. Lampert
	President

Get the next $CALT alert in real time by email

Date	Price Target	Rating	Analyst
6/20/2023	$60.00	Buy	H.C. Wainwright
3/1/2023	$18.00	Neutral	Guggenheim
12/20/2021	$52.00 → $62.00	Buy	HC Wainwright & Co.

SEC Form SC 13G/A filed by Calliditas Therapeutics AB (Amendment)

Chat with this insight

Recent Analyst Ratings for
$CALT

$CALT
Large Ownership Changes

This live feed shows all institutional transactions in real time.

Amendment: SEC Form SC 13D/A filed by Calliditas Therapeutics AB

Amendment: SEC Form SC 13D/A filed by Calliditas Therapeutics AB

Amendment: SEC Form SC 13G/A filed by Calliditas Therapeutics AB

$CALT
Analyst Ratings

Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

H.C. Wainwright initiated coverage on Calliditas Therapeutics AB with a new price target

Guggenheim initiated coverage on Calliditas Therapeutics AB with a new price target

HC Wainwright & Co. reiterated coverage on Calliditas Therapeutics with a new price target

$CALT
Leadership Updates

Live Leadership Updates

Calliditas Therapeutics appoints Maria Törnsén as President North America

Celularity Appoints Industry Leader Diane Parks to its Board of Directors

Phathom Pharmaceuticals Announces Appointment of Molly Henderson as Chief Financial and Business Officer

$CALT
FDA approvals

Live FDA approvals issued by the Food and Drug Administration and FDA breaking news

$CALT
Press Releases

Fastest customizable press release news feed in the world

$CALT
Financials

Live finance-specific insights

FDA Approval for TARPEYO issued to CALLIDITAS THERAPEUTICS AB

Delisting of Calliditas Therapeutics AB (publ) from Nasdaq Stockholm

Notice of extraordinary meeting of Calliditas Therapeutics AB (publ)

Calliditas Therapeutics takes certain corporate actions following announcement by Asahi Kasei

Calliditas Interim Report January to June 2024

Invitation to the presentation of Calliditas's interim report January - June 2024

Bulletin from the annual general meeting of Calliditas Therapeutics AB (publ)

$CALT
SEC Filings

SEC Form 15F-12B filed by Calliditas Therapeutics AB

SEC Form 25-NSE filed by Calliditas Therapeutics AB

Amendment: SEC Form SC TO-T/A filed by Calliditas Therapeutics AB

SEC Form SC 13G/A filed by Calliditas Therapeutics AB (Amendment)

Chat with this insight

Recent Analyst Ratings for $CALT

$CALT Large Ownership Changes

This live feed shows all institutional transactions in real time.

Amendment: SEC Form SC 13D/A filed by Calliditas Therapeutics AB

Amendment: SEC Form SC 13D/A filed by Calliditas Therapeutics AB

Amendment: SEC Form SC 13G/A filed by Calliditas Therapeutics AB

$CALT Analyst Ratings

Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

H.C. Wainwright initiated coverage on Calliditas Therapeutics AB with a new price target

Guggenheim initiated coverage on Calliditas Therapeutics AB with a new price target

HC Wainwright & Co. reiterated coverage on Calliditas Therapeutics with a new price target

$CALT Leadership Updates

Live Leadership Updates

Calliditas Therapeutics appoints Maria Törnsén as President North America

Celularity Appoints Industry Leader Diane Parks to its Board of Directors

Phathom Pharmaceuticals Announces Appointment of Molly Henderson as Chief Financial and Business Officer

$CALT FDA approvals

Live FDA approvals issued by the Food and Drug Administration and FDA breaking news

$CALT Press Releases

Fastest customizable press release news feed in the world

$CALT Financials

Live finance-specific insights

FDA Approval for TARPEYO issued to CALLIDITAS THERAPEUTICS AB

Delisting of Calliditas Therapeutics AB (publ) from Nasdaq Stockholm

Notice of extraordinary meeting of Calliditas Therapeutics AB (publ)

Calliditas Therapeutics takes certain corporate actions following announcement by Asahi Kasei

Calliditas Interim Report January to June 2024

Invitation to the presentation of Calliditas's interim report January - June 2024

Bulletin from the annual general meeting of Calliditas Therapeutics AB (publ)

$CALT SEC Filings

SEC Form 15F-12B filed by Calliditas Therapeutics AB

SEC Form 25-NSE filed by Calliditas Therapeutics AB

Amendment: SEC Form SC TO-T/A filed by Calliditas Therapeutics AB

Recent Analyst Ratings for
$CALT

$CALT
Large Ownership Changes

$CALT
Analyst Ratings

$CALT
Leadership Updates

$CALT
FDA approvals

$CALT
Press Releases

$CALT
Financials

$CALT
SEC Filings